TOMORROW CRYPTO GROUP INC. TO BECOME PUBLICLY TRADED THROUGH PROPOSED MERGER WITH GLOBALINK INVESTMENT INC.

Tomorrow Crypto Group Inc. (“Tomorrow Crypto”) is a Bitcoin/Ethereum (“ETH”) mining company in the United States dedicated to becoming a vertically-integrated provider of cryptocurrency mining infrastructure and services in the global blockchain ecosystem. Transaction values Tomorrow Crypto at an enterprise…

Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studies REYKJAVIK, ICELAND (July 20, 2022) –…

EDAP Announces Focal One® HIFU Reimbursement Raised to Urology APC Level 6 Under CMS Outpatient Prospective Payment System (OPPS) Proposed Rule for CY23

Proposed rule, if adopted for CY23, would increase Medicare Payment for a Focal One HIFU procedure completed on an outpatient basis at a hospital LYON, France, July 18, 2022 — EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader…

Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®  

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion in 2021 The patient study is expected to enroll…

Canoe Financial Announces Receipt Of Securityholder Approval In Respect Of Proposed Fund Merger, and Risk Rating Change

CALGARY, Alberta, June 30, 2022 (GLOBE NEWSWIRE) — Canoe Financial LP (“Canoe Financial”) is pleased to announce that it has obtained securityholder approval for the proposed fund merger (the “Merger”) described in the table below. The Merger is expected to be…

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients Submission builds on Sandoz’ well established biosimilar immunology portfolio in…

Ninepoint Partners Announces Voting Results for Proposed Restructuring of Private Debt Funds

TORONTO, June 16, 2022 (GLOBE NEWSWIRE) — Ninepoint Partners LP (Ninepoint Partners) announces today unitholder approval to restructure the Ninepoint Canadian Senior Debt Fund, Ninepoint Monroe U.S. Private Debt Fund and Ninepoint Monroe U.S. Private Debt Fund – Canadian $…

DSM and Firmenich confirm leadership team for proposed combined company DSM-Firmenich

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION. NOT FOR GENERAL…

Water Ways Provides Update on the Previously Announced Proposed Acquisition of the Chilean Provider – Hidrotop

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, June 09, 2022 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (FRA: WWT) (“WWT” or the “Company“), a global provider of Israeli-based agriculture technology, providing water irrigation solutions…

Altair Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

TROY, Mich., June 9, 2022 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational science and artificial intelligence, today announced its intention to offer, subject to market conditions and other factors, $200 million aggregate principal amount of Convertible Senior Notes due…